findmyKOL

Charles Fuchs, MD, MPH

Enriched profile

Chief Medical Officer, Tubulis GmbH (appointed January 8, 2026; based in Tubulis' U.S. Cambridge, MA office); immediately prior: Senior Vice President and Global Head of Oncology & Hematology Product Development, Genentech and Roche (2021-Jan 2026) · Tubulis GmbH

ORCID↗NPINone on file
Region🇩🇪 GermanySpecialtyMedical OncologyFocusColorectal Cancer Treatments and Studies+4
Active KOLfindmyKOL typefindmyKOL type: our influence ranking, shown when you reveal the full profileLatest publication2026Online presenceverified 2026PaymentsNot attributedNIH funding2016–2022Why? →

Charles Fuchs is Chief Medical Officer, Tubulis GmbH (appointed January 8, 2026; based in Tubulis' U.S. Cambridge, MA office); immediately prior: Senior Vice President and Global Head of Oncology & Hematology Product Development, Genentech and Roche (2021-Jan 2026) at Tubulis GmbH. OpenAlex indexes 1,721 publications with 114,486 citations (h-index 172); ClinicalTrials.gov lists 7 registered studies with this person as an investigator.

Data verified 14 Aug 2026

Overview

Updated 27 Aug 2026

Charles S. Fuchs is Chief Medical Officer, Tubulis GmbH (appointed January 8, 2026. The public record shows 1,721 publications with 114,486 citations (h-index 172), centered on Colorectal Cancer Treatments and Studies, Pancreatic and Hepatic Oncology Research, Gastric Cancer Management and Outcomes. It also documents an investigator role on 7 registered clinical trials, 5 NIH-funded awards (2016–2022).

  • Most recent indexed publication: 2026 · Cancer immunology research
  • Top research focus: Colorectal Cancer Treatments and Studies
  • 7 registered trials on ClinicalTrials.gov

Generated from the cited public record · current as of 27 Aug 2026. Every fact links its source below.

Indications focus

from trials led + research topics
Colorectal Cancer2 trialsGastroesophageal Cancer2 trialsPancreatic Cancer2 trialsStomach Neoplasms2 trialsRectal Neoplasms1 trialEsophageal Neoplasms1 trial

Research focus

OpenAlex concept fingerprint
Colorectal Cancer Treatments and StudiesPancreatic and Hepatic Oncology ResearchGastric Cancer Management and OutcomesColorectal Cancer Screening and DetectionGenetic factors in colorectal cancer

Drugs & molecules

across trials, industry payments and publications
FluorouracilClinical trials4Industry payments—Publications1IrinotecanClinical trials2Industry payments—Publications3LeucovorinClinical trials2Industry payments—Publications1
8 more drug records behind the reveal.Reveal →

Works with

trial sponsors and companies reporting payments
Dana-Farber Cancer InstituteClinical trials5Industry payments—Alliance for Clinical Trials in OncologyClinical trials1Industry payments—National Cancer Institute (NCI)Clinical trials1Industry payments—

Scholarship

indexed output and impact (OpenAlex)
View publications ↓
1,721publications

Distinct works indexed by OpenAlex, matched via ORCID; 17 in PubMed.

114,486citations

Total citations across indexed works.

172h-index

Hirsch index (OpenAlex). i10-index 764.

Clinical & industry

trials, payments and federal funding
7clinical trials

Investigator role on registered studies.

View trials ↓
—payment companies

Not shown. No U.S. clinical registration on file.

5NIH grants · 2016–2022

Federally funded research awards.

View funding ↓

This is a research profile, built on the published record. There's no U.S. clinical registration (NPI) on file, so facts that hang off one (clinical specialty, industry payments) aren't shown. We'd rather leave a gap than guess. Why? →

Contact

No public contact details on file. Research profiles have no U.S. clinical registration, so there's no federal registry record to draw an address or phone from. Why? →

Clinical trials

Updated 27 Aug 2026

Listed as an investigator on 7 registered studies on ClinicalTrials.gov. The most recent:

4 more trial records behind the reveal.Reveal →

Industry payments

Not shown. This person has no U.S. clinical registration (NPI) on file, so we can't reliably tie industry payments reported to CMS to them. We'd rather leave a gap than guess. Why? →

NIH funding

Updated 27 Aug 2026

5 NIH research awards on record, funded 2016–2022 per NIH RePORTER. The latest:

163 more award records behind the reveal.Reveal →

Publications

Updated 27 Aug 2026

Their five most recent publications, matched to their ORCID record and linked to PubMed.

12 more publications behind the reveal.Reveal →

Most-cited works

by citation count (OpenAlex)
  1. 01
    Fusobacterium nucleatum Potentiates Intestinal Tumorigenesis and Modulates the Tumor-Immune Microenvironment
    2,732 citations2013
    doi.org ↗
  2. 02
    A Randomized Controlled Trial of Fluorouracil Plus Leucovorin, Irinotecan, and Oxaliplatin Combinations in Patients With Previously Untreated Metastatic Colorectal Cancer
    2,268 citations2003
    doi.org ↗
  3. 03
    Ramucirumab monotherapy for previously treated advanced gastric or gastro-oesophageal junction adenocarcinoma (REGARD): an international, randomised, multicentre, placebo-controlled, phase 3 trial
    2,201 citations2013
    doi.org ↗
  4. 04
    Safety and Efficacy of Pembrolizumab Monotherapy in Patients With Previously Treated Advanced Gastric and Gastroesophageal Junction Cancer
    1,814 citations2018
    doi.org ↗
  5. 05
    Analysis of <i>Fusobacterium</i> persistence and antibiotic response in colorectal cancer
    1,525 citations2017
    doi.org ↗
1,716 more cited works behind the reveal.Reveal →

Network

Updated 27 Aug 2026

The people this person publishes with most, by number of co-authored papers. Names link to their own profile when we have one.

Edward L. Giovannucci768Shuji Ogino590Jeffrey A. Meyerhardt526
37 more collaborators behind the reveal.Reveal →

Online presence

Updated 27 Aug 2026

This person's own public accounts first, then places where others mention them. Two different things, listed separately.

Owned accounts

public accounts run by this person
  • Doximity

    doximity.com/pub/charles-fuchs-md-2203d6ea

    verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →doximity.com ↗
  • Doximity

    doximity.com/pub/charles-fuchs-md-3baa7c8f

    verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →doximity.com ↗
  • LinkedIn

    linkedin.com/in/charles-fuchs-14391a14

    verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →linkedin.com ↗
3 more verified accounts behind the reveal.Reveal →

Mentions by others

where others cite or feature them
  • Facebook

    facebook.com/SmilowCancerHospital/videos/dr-charles-fuchs-director-of-yale-cancer-center-and-physician-in-chief-of-smilow/715800245841445

    verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →facebook.com ↗
  • Other

    medicine.yale.edu/media-player/dr-charles-fuchs-discusses-approval-of-pembrolizumab-for-stomach-cancer

    verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →medicine.yale.edu ↗
  • Other

    medicine.yale.edu/media-player/dr-charles-fuchs-profile

    verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →medicine.yale.edu ↗
5 more mentions behind the reveal.Reveal →

We list an account only when the public record ties it to this person. verified means we've confirmed the match in more than one place; provisional means it looks right but we're still confirming.

Background & recognition

Updated 27 Aug 2026

Credentials, appointments and honors, newest first, each linked to the public source it came from.

Education

degrees and training on record
  • M.P.H.

    Harvard School of Public Health

    1994
    verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →news.yale.edu ↗
  • M.D.

    Harvard Medical School

    1986
    verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →news.yale.edu ↗
  • Internal medicine residency (chief medical resident)

    Brigham and Women's Hospital

    verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →news.yale.edu ↗
  • Medical oncology fellowship

    Dana-Farber Cancer Institute

    verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →news.yale.edu ↗

Editorial & leadership roles

journal and society appointments
  • Former Director

    Yale Cancer Center

    2021
    verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →news.yale.edu ↗
  • Former Physician-in-Chief

    Smilow Cancer Hospital

    2021
    verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →news.yale.edu ↗
  • Former Chief

    Gastrointestinal Oncology Division, Dana-Farber Cancer Institute

    verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →aacr.org ↗

Awards & honors

honors on the public record

Secondary affiliations

appointments beyond the home institution
1 more affiliation behind the reveal.Reveal →

Media & interviews

press, podcasts and appearances
3 more media items behind the reveal.Reveal →

Every item links to where we found it. verified means we've confirmed it in more than one place; provisional means we found it and are still confirming.

Similar KOLs

Other experts from the same institution or the same specialty.